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Original Article
Introduction
Adequate control of troublesome regurgitation and extra-
esophageal manifestation such as laryngitis, asthma, 
chronic cough, and dental erosions1 in chronic gastro-
esophageal reflux disease (GERD) patients remains a 
therapeutic concern.2,3 Medical therapy with proton pump 
inhibitors (PPIs) causes a modest and considerably less 
symptomatic relief of regurgitation4 and extraesophageal 
symptoms5-10 compared with heartburn. On the other 
hand, despite its proven long-term effectiveness, laparo-
scopic Nissen fundoplication (LNF) is associated with 
potential side effects such as gas bloat, dysphagia, and 
uncontrolled flatulence.11 Additionally, failure of medical 
therapy has been considered predictive of nonsatisfactory 
outcomes of LNF.3 Recently, many attempts have been 
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Transoral Incisionless Fundoplication 
Effective in Eliminating GERD Symptoms 
in Partial Responders to Proton Pump 
Inhibitor Therapy at 6 Months:  
The TEMPO Randomized Clinical Trial
Karim S. Trad, MD1,2, William E. Barnes, MD3, Gilbert Simoni, MD4,  
Ahmad B. Shughoury, MD5,6, Peter G. Mavrelis, MD5,6, Mamoon Raza, MD7,8, 
Jeffrey A. Heise, MD9, Daniel G. Turgeon, MD1,2, and Mark A. Fox, MD10,11
Abstract
Background. Incomplete control of troublesome regurgitation and extraesophageal manifestations of chronic 
gastroesophageal reflux disease (GERD) is a known limitation of proton pump inhibitor (PPI) therapy. This multicenter 
randomized study compared the efficacy of transoral incisionless fundoplication (TIF) against PPIs in controlling these 
symptoms in patients with small hiatal hernias. Methods. Between June and August 2012, 63 patients were randomized 
at 7 US community hospitals. Patients in the PPI group were placed on maximum standard dose (MSD). Patients in the 
TIF group underwent esophagogastric fundoplication using the EsophyX
2
 device. Primary outcome was elimination of 
daily troublesome regurgitation or extraesophageal symptoms. Secondary outcomes were normalization of esophageal 
acid exposure (EAE), PPI usage and healing of esophagitis. Results. Of 63 randomized patients (40 TIF and 23 PPI), 3 
were lost to follow-up leaving 39 TIF and 21 PPI patients for analysis. At 6-month follow-up, troublesome regurgitation 
was eliminated in 97% of TIF patients versus 50% of PPI patients, relative risk (RR) = 1.9, 95% confidence interval 
(CI) = 1.2-3.11 (P = .006). Globally, 62% of TIF patients experienced elimination of regurgitation and extraesophageal 
symptoms versus 5% of PPI patients, RR = 12.9, 95% CI = 1.9-88.9 (P = .009). EAE was normalized in 54% of TIF 
patients (off PPIs) versus 52% of PPI patients (on MSD), RR = 1.0, 95% CI = 0.6-1.7 (P = .914). Ninety percent of TIF 
patients were off PPIs. Conclusion. At 6-month follow-up, TIF was more effective than MSD PPI therapy in eliminating 
troublesome regurgitation and extraesophageal symptoms of GERD.
Keywords
transoral incisionless fundoplication (TIF), EsophyX, extraesophageal GERD symptoms, regurgitation, proton pump 
inhibitor (PPI), heartburn
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made to develop an alternative and less invasive treat-
ment that would bridge the gap between medical therapy 
and LNF.
Several retrospective and prospective studies have 
reported that transoral incisionless fundoplication (TIF) 
performed with EsophyX device (EndoGastric Solutions, 
Redmond, WA) is capable of improving GERD symp-
toms and patient satisfaction of those suffering from 
chronic GERD when the associated hiatal hernia defect is 
small (≤2 cm).12 A notable absence of randomized studies 
evaluating the procedure has prevented a better definition 
of its role in the management of chronic GERD.13
The TEMPO trial (TIF EsophyX vs Medical PPI Open 
Label Trial) compared the efficacy of the TIF procedure 
against maximal dose PPI therapy in controlling regurgi-
tation and extraesophageal symptoms of GERD in 
patients who partially responded to PPIs. The primary 
hypothesis was that TIF would be more effective than 
PPIs in eliminating daily troublesome regurgitation or 
extraesophageal GERD symptoms at 6-month follow-up. 
The secondary hypotheses were that the majority of TIF 
patients would normalize their esophageal acid exposure 
(EAE) compared with baseline and that the majority of 
TIF patients would be completely off PPIs.
Methods
Study Design
This multicenter, open label, randomized, comparative 
study was conducted at 7 study sites in the United States. 
The institutional review board of the participating institu-
tions approved the study protocol. Written consent was 
obtained from all patients before randomization after all 
critical information about the study had been explained in 
detail. Patients who had met the eligibility criteria were 
randomly assigned to receive either TIF or maximum 
dose PPI therapy with a target allocation ratio of 2:1. 
There were no important changes to methods after study 
initiation and no interim analyses for efficacy were 
performed.
Patients
Patients experiencing persistent daily troublesome regur-
gitation or extraesophageal GERD symptoms (with or 
without heartburn) on daily PPIs were deemed eligible 
for the study if they had documented abnormal EAE as 
determined by ambulatory 48-hour pH monitoring while 
off PPI therapy for at least 7 days (% total time pH < 4 
occurred for >5.3% of the recording time14) and hiatal 
hernia measurements not exceeding 2 cm in both axial 
length and in greatest transverse dimension. A complete 
list of inclusion and exclusion criteria is presented in 
Table 1. Eligible patients were randomly assigned to 
receive either TIF or maximum standard dose (MSD) PPI 
therapy. Patients in the PPI group were required to take 
the MSD of currently used PPI in an attempt to optimize 
control of their GERD symptoms. The same brand of PPI 
used by individual patients at screening was prescribed 
by investigators at the maximal allowed dose per manu-
facturer’s recommendations and provided free of charge 
Table 1. Inclusion and Exclusion Criteria.
Inclusion Criteria Exclusion Criteria
Age: 18-80 years Body mass index (BMI) >35 kg/m2
Gastroesophageal reflux disease duration: >1 
year
Hiatal hernia >2 cm in axial length and/or >2 cm in greatest transverse 
dimensions
History of daily proton pump inhibitors (PPIs) 
use >6 months
Esophagitis grade C or D; Barrett’s esophagus >2 cm; esophageal ulcer; fixed 
esophageal stricture or narrowing
Troublesome atypical symptoms and/or 
regurgitation (with or without heartburn) while 
on daily PPI therapy
Portal hypertension and/or varices
Abnormal 48-hour pH off PPIs (total % time 
pH < 4 > 5.3%)
Active gastroduodenal ulcer disease
Hill grade I or II Gastroparesis, gastric outlet obstruction, or stenosis
Willingness to undergo pH testing Coagulation disorder
Willingness to adhere to postoperative diet 
for 6 weeks
History of any of the following: resective gastric or esophageal surgery, 
antireflux surgery with anatomy unsuitable for transoral incisionless 
fundoplication (TIF) procedure per physician judgment, cervical spine 
fusion, Zenker’s diverticulum, esophageal epiphrenic diverticulum, achalasia, 
scleroderma ordermatomyositis, eosinophilic esophagitis, or cirrhosis
Availability for follow-up visits Pregnancy or plans of pregnancy in the 12 months following treatment
Willingly and cognitively signed informed 
consent
Enrollment in another device or drug study that may confound the results
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to each patient randomized to the PPI group. A complete 
listing of PPI brands used in this study is provided in 
Table 2. Patients in the TIF group underwent endoscopic 
fundoplication using the latest iteration of the EsophyX
2
 
device to perform the standardized TIF-2.0 protocol pre-
viously described elsewere.15,16 In brief, under general 
anesthetic, the EsophyX device was gently introduced 
over the flexible endoscope into the stomach under con-
stant endoscopic visualization. The helical retractor was 
engaged into the tissue slightly distal to Z line. Then, in 
combination with the tissue manipulating elements, the 
fundus of the stomach was folded up and around the dis-
tal esophagus. After tissue handling elements were appro-
priately positioned and locked into place, the invaginator 
was activated to allow the separation of the gastroesopha-
geal junction from the diaphragm. The polypropylene 
“H” fasteners were delivered through the tissue. The 
same maneuvers were repeated at 3 additional positions 
Table 2. Baseline Characteristics of Study Patients.a
Characteristics TIF Group (n = 39) PPI Group (n = 21) P Valuesb
Female, n (%) 20 (51) 13 (62) .587
Age in years, median (range)c 54.8 (35.7-73.3) 50.1 (32.5-63.3) .206
 < 50, n (%) 14 (36) 10 (48) .418
 50-65, n (%) 20 (51) 11 (52) >.999
 > 65, n (%) 5 (13) 0 (0) .152
Body mass index, kg/m2, median (range)c 28.9 (20.5-34.9) 28.3 (24.5-34.9) .871
GERD symptom duration in years, median (range)c 10 (2-50) 10 (1-20) .586
PPI therapy duration in years, median (range)c 7 (1-25) 8 (1-22) .861
Barrett’s esophagus, <2 cm, n (%) 1 (3) 0 (0) >.999
Esophagitis (Los Angeles grade), n (%) 20 (51) 13 (62) .587
 A, n (%) 1 (5) 4 (31) .066
 B, n (%) 19 (95) 9 (69) .066
Hill grade, n (%) 37 (95) 18 (86) .332
 I, n (%) 5 (14) 2 (11) >.999
 II, n (%) 32 (86) 16 (89) >.999
Hiatal hernia, n (%) 36 (92) 16 (76) .114
 Axial length ≤1cm, n (%) 14 (39) 3 (19) .208
 Axial length >1cm and ≤2 cm, n (%) 22 (61) 13 (81) .208
GERD Health-Related Quality of Life score, median (range)
 On PPIsc 27 (4-48) 26 (16-39) .896
 Off PPIsc 34 (7-50) 34 (21-49) .536
Heartburn score, median (range)
 On PPIsc 19 (4-30) 17 (7-27) .560
 Off PPIsc 23.5 (4-30) 24 (16-30) .733
Reflux Symptom Index score, median (range)
 On PPIsc 23 (3-43) 23 (4-35) .774
 Off PPIsc 25 (2-42) 27 (17-42) .211
Reflux Disease Questionnaire score, median (range)
 On PPIsc 3.2 (0-5) 3.4 (0.3-4.0) .721
 Off PPIsc 3.9 (0.6-5.0) 4.0 (2.3-5.0) .191
Total % time pH < 4, median (range)1 9.6 (5.4-19.5) 9.3 (5.4-17.2) .636
Patients on single dose of PPI at entry, n (%) 27 (69) 16 (76) .765
Patients on Omeprazole at entry, n (%) 16 (41) 10 (48) .785
Patients on Esomeprazole at entry, n (%) 9 (23) 8 (38) .243
Patients on Lansoprazole at entry, n (%) 5 (13) 1 (5) .412
Patients on Pantoprazole at entry, n (%) 6 (15) 1 (5) .404
Patients on Dexlansoprazole at entry, n (%) 3 (8) 1 (5) >.999
Abbreviations: TIF, transoral incisionless fundoplication; PPI, proton pump inhibitor; GERD, gastroesophageal reflux disease.
aHill grade and esophagitis were evaluated with screening endoscopy. Of 12 patients in the TIF group who were taking double-dose PPIs at entry, 
6 (50%) patients were on Omeprazole, 3 (25%) on Pantoprazole, 2 (17%) on Lansoprazole, and 1 (8%) on Esomeprazole. In the PPI group, of 5 
patients who were taking double-dose PPIs, 3 (60%) patients were on Esomeprazole and 2 (40%) were on Omeprazole.
bP values were calculated using 2-tailed Fisher exact test unless indicated otherwise.
cMann–Whitney U test.
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to create full thickness, partial, gastroesophageal fundo-
plication. TIF patients were generally discharged 24 
hours postprocedure and were asked to follow the stan-
dard dietary and physical restrictions previously 
described.15 Patients were evaluated and followed in 
community-based practices by clinical teams led by 4 
surgeons and 3 gastroenterologists. TIF procedures were 
performed in the associated community hospitals.
Preprocedure Evaluation
All patients enrolled in the study underwent thorough 
preprocedure evaluation, including complete history, 
physical examination, symptom assessment, esophago-
gastroduodenoscopy (EGD), and 48-hour pH monitoring. 
Gastroesophageal manometry was performed in selected 
patients to rule out diagnoses of achalasia or severe 
esophageal dysmotility disorders, whenever warranted 
by clinical suspicion. In some cases, a barium swallow 
was obtained to further evaluate esophageal anatomy and 
esophageal clearance and to rule out any suspected 
esophageal structural problems.
All patients underwent two screening visits (Figure 1). 
During the first screening visit, demographic characteris-
tic of study patients, frequency, dose, and duration of 
GERD medication usage were collected while patients 
were on currently used PPIs. Symptom assessment was 
carried out using three validated GERD-specific instru-
ments: (a) Gastroesophageal Health-Related Quality of 
Life (GERD-HRQL), (b) Reflux Symptom Index (RSI), 
and (c) Reflux Disease Questionnaire (RDQ). Patients 
who suffered from daily troublesome GERD symptoms 
other than heartburn, such as atypical GERD symptoms 
or regurgitation while taking daily PPIs were eligible to 
undergo further testing. These patients were asked to dis-
continue PPI therapy for 7 days and to return for the sec-
ond screening visit.
Symptom assessment was repeated off PPI therapy for 
7 days during the second screening visit using the same 
questionnaires. All patients underwent EGD and 48-hour 
pH test off PPIs to objectively confirm the diagnosis of 
GERD. EGD was used to confirm the presence of esoph-
agitis, assess the size of hiatal hernia, and evaluate the 
appearance of gastroesophageal junction using Hill grade 
classification. Biopsies were performed whenever indi-
cated by the findings at endoscopy. A 48-hour pH test was 
performed after discontinuation of PPIs for 7 days. Per 
protocol, EAE was considered abnormal if % total time 
pH <4 occurred for >5.3% of the recording time.14
Follow-up Evaluation
Three follow-up visits were scheduled (2 weeks, 3 months, 
and 6 months) for all patients. Postprocedure symptoms, 
adverse events, and medication usage for all patients were 
recorded at all follow-up visits. Patients in the TIF group 
were required to completely discontinue PPI usage 14 
days after the procedure and to follow the postprocedure 
diet for a total of 6 weeks.
At the 6-month follow-up visit, patients in the PPI 
(control) group completed the GERD-HRQL, RSI, and 
RDQ questionnaires and underwent EGD and 48-hour 
pH monitoring while on MSD PPIs. Patients in the TIF 
group completed the same 3 questionnaires and tests 
6 months postprocedure while off PPIs. In addition, the 
minority of patients in the TIF group who had resumed 
taking PPIs 6 months postprocedure were asked to com-
plete the same questionnaires while on PPI therapy.
Study End Points and Efficacy Assessments
The primary endpoint was elimination of daily troublesome 
GERD symptoms other than heartburn as evaluated by 
GERD-HRQL, RSI, and RDQ instruments at 6-month fol-
low-up. GERD-HRQL is designed and validated to evalu-
ate typical GERD symptoms by measuring 10 items 
(6 related to heartburn, 2 to dysphagia, 1 to bloating, and 1 
to the impact of medications on daily life) on the visual ana-
log scale ranging from 0 (no symptoms) to 5 (worst symp-
toms).17 A higher total GERD-HRQL score (range from 0 to 
50) indicates more severe GERD.15 RSI is a 9-item vali-
dated questionnaire used to measure atypical GERD symp-
toms such as hoarseness, throat clearing, excess throat 
mucus, dysphagia, and cough.18 The scale for each individ-
ual item ranges from 0 (no problem) to 5 (severe problem), 
with a maximum total score of 45 and a normality threshold 
of ≤13.18 RDQ is a 12-item questionnaire that was designed 
to assess the frequency and severity of heartburn (4 items 
measuring the frequency and severity of pain and burning 
behind the breastbone), regurgitation (4 items measuring 
the frequency and severity of acid taste in the mouth and 
movement of the material upward from the stomach), and 
dyspeptic complaints (4 items measuring the frequency and 
severity of pain or burning in the upper stomach).19 
Response options range from 0 (not present) to 5 (daily) for 
frequency and 0 (not present) to 5 (severe) for severity. 
Each patient’s score is calculated as the mean of item 
responses with higher scores indicating more severe or fre-
quent symptoms.19 In the current study, elimination of daily 
troublesome symptoms was defined as a score ≤2 on the 
GERD-HRQL and RSI questionnaires; in the case of RDQ, 
elimination of moderate to severe regurgitation with the fre-
quency reduced to 1 day a week or less (this corresponds to 
scores of ≤2 for frequency and severity of regurgitation). 
The RSI questionnaire was used to assess atypical GERD 
symptoms while RDQ was used to assess regurgitation. 
GERD-HRQL was used to assess heartburn, bloating, and 
satisfaction with current health condition.
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Secondary efficacy endpoints were normalization of 
EAE, healing of esophagitis, and PPI use. Complete dis-
continuation of PPI therapy was considered clinically sig-
nificant for TIF patients.
In addition to primary and secondary endpoints, 
patient satisfaction, incidence of de novo postfundoplica-
tion symptoms (bloating, excess flatulence, and dyspha-
gia) and serious adverse events were documented.
Figure 1. Screening assessments of study patients.
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Sample Size and Randomization
An unequal randomization allocation of 2:1 was chosen 
primarily to reduce the costs associated with this trial. A 
sample size of n = 42 (28 TIF, 14 PPI) was needed for an 
80% power to detect a significant difference (α of .05) 
between the 2 groups. The power calculation was based 
on the assumption that >70% of the patients randomized 
to the TIF group would have their daily troublesome 
symptoms eliminated compared with ≤20% in the PPI 
group. To account for eventual attrition due to loss of 
follow-up and individual patient refusal to undergo EGD 
or 48-hour pH monitoring at follow-up, 12 more patients 
were allocated to TIF group and 9 more patients were 
allocated to PPI group (n = 63; 40 TIF, 23 PPI). Using a 
random number generator software, an independent stat-
istician established the randomization sequence in blocks 
of 9 with stratification according to participating centers. 
Patient assignment was provided to participating centers 
via sealed opaque envelopes, and was concealed from 
clinical staff and patients during the 2 screening visits. 
The envelopes with randomization were opened after the 
second screening visit, in the presence of patients who 
had met all the eligibility criteria.
Statistical Analysis
Data were collected on a 37-page case report form and 
then transferred to a study specific and secured electronic 
database (FileMaker Pro 10, Santa Clara, CA). The 
Shapiro–Wilk test was used for normality testing. 
Continuous, normally distributed data were presented as 
the mean ± standard deviation (SD). Data with skewed 
distribution were reported as the median (range). Fisher 
exact test was used to determine the significance of 2 × 2 
contingency tables. Unadjusted relative risk (RRs) and 
95% confidence intervals (CIs) were calculated to esti-
mate the relative effect of TIF as compared with that of 
PPI therapy for all outcomes. Two-tailed Mann–Whitney 
U test was used to assess the difference between nonpara-
metric data. The P values for changes at follow-up com-
pared with those at baseline within the same treatment 
group were calculated using the 2-tailed paired t test or 
the Wilcoxon signed rank test; in case of proportions, 
McNemar’s test was used. A P value of less than .05 was 
considered significant. Statistical analyses were per-
formed using JMP 10.0 software.
Results
Baseline Characteristics of the Patients
Between June and August 2012, 63 patients were ran-
domized into the study; 40 patients into the TIF group 
and 23 patients into the PPI group. All randomized 
patients had abnormal distal esophageal acid exposure. 
The flowchart of screened, enrolled, and analyzed patients 
is shown in Figure 2. The treatment groups were well 
matched at entry (Table 2). There were no differences 
between treatment groups in the clinical features of the 
disease, such as duration of symptoms, duration of PPI 
use before procedure and/or severity of the disease based 
on symptom score and abnormal acid exposure as 
expressed in % time pH < 4. Overall, a slight majority of 
patients were female (33 of 63, 52%) and only 5 of 63 
patients (8%) were older than 65 years. Medication dos-
age and PPIs used before randomization are shown in 
Table 2.
Safety and Procedure Outcomes
All TIF procedures were performed under general anes-
thesia and were completed successfully without conver-
sion to open or laparoscopic approaches. In 37 of 39 
(95%) cases no related issues with the EsophyX
2
 device 
were reported. In one case, the anterior wire used to trans-
fer fasteners from the cartridge to a stylet was damaged, 
leading the physician to complete procedure with the pos-
terior wire only. In another case, the gastric distention 
was suboptimal, making the procedure technically more 
challenging. The average time required to complete the 
procedure, measured from device introduction to removal, 
was 38 minutes (range = 20-68 minutes, SD = 14 min-
utes). On average, 21 (range = 16-30, SD = 4) contribut-
ing fasteners were used to create an esophagogastric 
fundoplication with a mean length of 2.8 cm (range = 
2.5-4 cm, SD = 0.5 cm) and a circumference of 290° 
(range 240° to 340°, SD = 18°) as evaluated by immedi-
ate postprocedure endoscopy. All 31 patients who were 
assigned a preprocedure Hill grade II were converted to 
Hill grade I. Postoperative valve adherence to the endo-
scope was tight in 79% (31/39) and moderate in 21% 
(8/39) of patients. All 36 hiatal hernias present at screen-
ing were reduced. Ninety-eight percent of patients were 
discharged within 24 hours. Two patients (5%) stayed in 
the hospital for 2 days; one for the management of post-
operative dizziness and nausea and one because of aller-
gic reaction to pain medication. There were no reports of 
any serious adverse event or hospital readmission associ-
ated with the TIF procedure.
Primary Outcome
Troublesome regurgitation, as evaluated by RDQ ques-
tionnaire, was eliminated in 97% (29/30) of patients in 
the TIF group (off PPIs) versus 50% (9/18) of patients in 
the PPI group (on MSD), RR = 1.9, 95% CI = 1.2-3.1 
(P < .001). Elimination of atypical GERD symptoms 
such as throat clearing, troublesome or annoying cough, 
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and hoarseness is charted in Figure 3. Globally, at 
6-month follow-up, complete elimination of all daily 
troublesome GERD symptoms other than heartburn was 
observed in 62% (24/39) of patients in the TIF group 
compared with 5% (1/21) in the PPI group, RR = 12.9, 
95% CI = 1.9-88.9 (P < .001).
Secondary Outcomes
Proton Pump Inhibitor Use. All patients in the TIF group 
were on daily PPI therapy before enrollment and random-
ization. At 6-month follow-up, 90% (35/39, 95% CI = 
0.76-0.97) of patients in the TIF group had completely 
stopped taking PPIs; 3% (1/39, 95% CI= <.0001 to 0.14) 
of patients were taking PPIs on demand and 8 % (3/39, 
95% CI = 0.02-0.21) were back on daily PPIs (Figure 3). 
Out of the 3 patients who were back on daily PPIs, 1 had 
reduced the original dose and 2 patients were on a higher 
dose. Of the 4 patients who were back on some form of 
PPI therapy, 1 remained dissatisfied with current health 
condition compared with 4 dissatisfied before TIF. Before 
enrollment in this study, of these 4 patients, 2 used PPIs 
for >20 years, one patient was on PPIs for 18 years and 1 
was taking PPIs for 7 years. Two of these 4 patients 
reported PPI use at 3-month follow-up; another 2 patients 
started taking the PPIs after 3-month follow-up visit. Of 
these 4 patients, 1 had normalized distal esophageal acid 
exposure (% total time pH < 4 was reduced from 9.9 to 
Figure 2. CONSORT flowchart of study patients.
Abbreviations: PPIs, proton pump inhibitors; TIF, transoral incisionless fundoplication.
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Figure 3. (A) Elimination of daily troublesome atypical symptoms as evaluated by RSI questionnaires at 6-month follow-up. (B) 
PPI use before TIF and at 6-month follow-up. (C) Quality-of-life scores in patients back on some form of PPI regimen. (D) Rate of 
healing or reduction of reflux esophagitis in both treatment arms. (E) Elimination of daily troublesome heartburn as evaluated by 
GERD-HRQL questionnaires.
Abbreviations: GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPIs, proton pump inhibitors; RDQ, Reflux Disease 
Questionnaire; RSI, Reflux Symptom Index; TIF, transoral incisionless fundoplication.
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3.1), 1 had improved (from 8.3 to 6.7), and 2 experienced 
increase in % total time pH < 4 (from 16.8 to 23.2 and 
from 15.7 to 22.2). Quality of life scores in patients back 
on PPIs are shown in Figure 3.
Objective Outcomes
In the TIF group, 54% (21/39) of patients had normalized 
esophageal acid exposure (off PPIs) compared to 52% 
(11/21) of patients on maximum dose PPI in the control 
group, RR = 1.0, 95% CI = 0.6-1.7 (P = .914). A signifi-
cant reduction of all 48-hour pH Bravo parameters was 
achieved in the TIF group; PPI therapy did not reach sig-
nificant reduction in the duration of the longest reflux 
episode (Table 3). Of patients with abnormal acid expo-
sure at 6 months postprocedure, 11% (2/18) in the TIF 
group were dissatisfied with their current health condi-
tion versus 100% dissatisfied (10/10) in the PPI group, 
RR = 0.13, 95% CI = 0.05-0.42 (P < .001). The reduction 
in the total GERD-HRQL, RSI, and RDQ scores in 
patients with abnormal esophageal acid exposure at 
6-month follow-up is shown in Table 4.
Endoscopic Assessment. All patients underwent endo-
scopic evaluation at 6-month follow-up. Complete heal-
ing or reduction in reflux esophagitis at 6 months was 
achieved in 90% (18/20) of patients in the TIF group (off 
PPIs) compared with 38% (5/13) in PPI group (on MSD), 
RR = 2.3, 95% CI = 1.2-4.7 (P = .018; Figure 3). Hiatal 
hernias remained reduced in all patients (36/36) who had 
a hiatal hernia before the TIF procedure. The valve 
appearance was judged as a Hill grade I in all cases. One 
patient who had short segment Barrett’s (<2 cm) before 
the procedure was found to have healed esophageal ero-
sions. This patient was off PPIs at 6-month follow-up and 
% total time pH < 4 was reduced from 9 before procedure 
to 1.5 at 6-month follow-up.
Ancillary Analyses
Heartburn, Patient Satisfaction, and Quality of Life. Ninety 
percent (28/31) of patients in the TIF group (off PPIs) 
reported elimination of daily troublesome heartburn versus 
13% (2/16) of patients in the PPI group (maximum daily 
dose); RR = 7.2, 95% CI = 2.0-26.6 (P = .003; Figure 3).
The median heartburn score in the TIF group, as 
evaluated by the GERD-HRQL questionnaire, improved 
significantly falling from 19 (range = 4-30) on PPIs 
before TIF to 2 (range = 0-26) off PPIs at 6-month fol-
low-up (P < .001); in the PPI group the median heart-
burn score also improved, decreasing from 17 (range = 
7-27) on screening to 11 (range = 0-27) on maximum 
Table 3. Changes in Mean 48-Hour pH Parameters From Before Treatments to 6-Month Follow-Up in Both Treatment Groups.
pH Parameters
TIF group (n = 39);  
Difference in Means (95% CI) P Valuesa
PPI group (n = 21); 
Difference in Means (95% CI) P Valuesa
Number of refluxes −59.9 (−80.7 to −39.2 <.001 −99.1 (−133.7 to −64.5) <.001
Number of long refluxes (>5 minutes) −4.1 (−6.1 to −2.0) <.001 −7.9 (−10.9 to −4.9 <.001
Duration of longest reflux, minutes −7.9 (−15.6 to −0.3) .042 −2.7 (−13.3 to 7.9) .598
Fraction time pH < 4, % −3.4 (−4.9 to −1.9) <.001 −5.5 (−7.4 to −3.6) <.001
DeMeester score −11.6 (−17.4 to −5.9) <.001 −16.5 (−23.0 to −10.0) <.001
Abbreviations: PPI, proton pump inhibitor; TIF, transoral incisionless fundoplication; CI, confidence interval.
aP values were calculated with paired t test.
Table 4. Changes in Mean Symptom Scores in Patients With Abnormal Distal Esophageal Acid Exposure From Before 
Treatments to 6-Month Follow-up in Both Treatment Groups.
Questionnaires/
Symptoms
TIF Group (n = 18); 
Difference in Means (95% CI) P Valuesa
PPI Group (n = 10); 
Difference in Means (95% CI) P Values
GERD-HRQL score −17.9 (−25.8 to −10.1) <.001 −3.6 (−9.6 to 2.4) .206
Heartburn score −12.2 (−18.1 to −6.3) <.001 −2.6 (−5.7 to 0.5) .090
Regurgitation score −2.9 (−3.5 to −2.2) <.001 −0.7 (−1.4 to 0) .042
RDQ score −2.7 (−3.3 to −2.0) <.001 −0.7 (−1.5 to 0.1) .071
RSI score −15.3 (−20.3 to −10.3) <.001 −1.3 (−6.3 to 3.7) .574
Abbreviations: GERD-HRQL, gastroesophageal reflux disease health-related quality of life; RDQ, Reflux Disease Questionnaire; RSI, Reflux 
Symptom Index; PPI, proton pump inhibitor; TIF, transoral incisionless fundoplication.
aP values were calculated using paired t test.
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PPI dose (P = .012). Figure 4 charts the progression of 
individual heartburn scores for all study patients from 
pretreatment values to 6-month follow-up. The median 
total GERD-HRQL score in the TIF group improved 
significantly from 27 (range = 4-48) on PPIs before TIF 
to 4 (range = 0-33) off PPIs at 6-month follow-up (P < 
.001); in the PPI group, the median total GERD-HRQL 
score also significantly improved from 26 (range = 
16-39) to 19 (range = 2-42) on maximum PPI dose (P = 
.009).
Patient satisfaction with current health condition, as 
evaluated by GERD-HRQL, improved significantly in 
the TIF group compared with baseline on PPIs (72% 
[28/39] satisfied while off PPIs vs 3% [1/39] satisfied 
before TIF while on PPIs [P < .001]). In the PPI group, 
patient satisfaction did not improve significantly (5% 
[1/21] satisfied while on maximum PPI dose vs 0% [0/21] 
satisfied at screening [P > .999]). Between-group analy-
sis revealed significantly more patients in the TIF group 
(72%, 28/39) were satisfied with their current health con-
dition after treatment compared with PPI group (5%, 
1/21), RR = 15.1, 95% CI = 2.2-103.1 (P = .006). 
Satisfaction with current health condition is charted in 
Figure 4.
The median total RSI score in the TIF group decreased 
significantly from 23 (range = 0-43) on PPIs before pro-
cedure to 3 (range = 0-25) off PPIs at 6-month follow-up 
(P < .001). A minor improvement in the median total RSI 
score in the control group on MSD PPI therapy did not 
reach statistical significance (from 23 [range = 4-35] at 
screening to 21 [range = 6-32] [P = .205]). Individual RSI 
scores are shown in Figure 4.
The median total RDQ score in the TIF group was sig-
nificantly decreased from 3.2 (range = 0-5) before TIF on 
PPIs to 0.2 (range = 0-2.4) off PPIs at 6-month follow-up 
(P < .001); the median total score for the regurgitation 
component of the RDQ questionnaire also significantly 
improved from 3.2 (range = 0-5) to 0 (range = 0-1.3; P < 
.001). In the PPI group, the median total RDQ score sig-
nificantly improved declining from 3.4 (range = 0.3-4.0) 
to 2.0 (range = 0.3-4.1; P < .001); however, the median 
total regurgitation score was insignificantly improved 
from 3.0 (range = 0.3-5.0) to 2.5 (range = 0.5-4.3) at 
6-month follow-up on maximum daily PPI dose (P = 
.111).
Dysphagia, Bloating, and Flatulence. Twelve of 39 (31%) 
patients in the TIF group and 8 of 21 (38%) patients in the 
PPI group suffered from daily troublesome dysphagia at 
screening (score >2). The elimination of daily trouble-
some dysphagia was experienced in 92% (11/12) of 
patients in the TIF group compared to 75% (6/8) in the 
PPI group, RR = 1.2, 95% CI = 0.8-1.9 (P = .366). In the 
TIF group, 1 patient reported worsening dysphagia (score 
from 1 to 4); in the PPI group, 2 patients reported worsen-
ing (score from 1 to 3 and score from 2 to 3). There were 
no reports of de novo dysphagia in either group. Bloating 
was improved in 79% (19/24) of patients in the TIF 
group, compared with 25% (4/16) in the PPI group, RR = 
3.2, 95% CI = 1.3-7.6 (P = .009). There were no reports 
of de novo bloating in either group. In the TIF group, of 5 
patients who reported daily troublesome bloating at 6 
month follow-up, 3 improved slightly (scores from 4 to 3) 
and 2 patients reported unchanged severity of bloating 
(scores 3 to 3 and scores 5 to 5); in the PPI group, of 12 
patients who reported daily troublesome bloating at 
6-month follow-up, 3 patients reported unchanged symp-
toms and 9 patients reported worsening of bloating. Sev-
enteen of 21 patients (81%) in the TIF group and 2 of 12 
(17%) in the PPI group reported elimination of daily 
troublesome flatulence at 6-month follow-up, RR = 4.9, 
95% CI = 1.3-17.5; P = .016). There were no reports of de 
novo troublesome flatulence in either group.
Discussion
The 3 major findings of this multicenter randomized 
study comparing TIF to maximum dose PPIs in a select 
group of patients with chronic GERD and hiatal hernias 
measuring less than 2 cm were as follows: (a) TIF was 
more effective than PPIs in elimination of troublesome 
regurgitation, (b) a majority of TIF patients (90%) were 
completely off PPIs at 6-month follow-up, and (c) TIF 
was equivalent to PPIs in normalizing distal EAE. To the 
best of our knowledge, this is the first time that an endo-
scopic anti-reflux procedure involving reconstruction of 
the gastroesophageal junction, was found to be more 
effective than PPIs in controlling troublesome typical and 
atypical GERD symptoms.20-22
The study population in both group consisted of 
patients who were partial responders to PPI therapy, as 
indicated by lower QOL scores on PPIs compared with 
the QOL scores off PPIs at screening (Table 2). We chose 
to use MSD PPI as the control group because patients suf-
fering ongoing symptoms despite medical therapy are 
routinely stepped up to maximum dosage in an attempt to 
control troublesome symptoms. Methodologically this 
design is justified by the fact that more than two thirds of 
patients were not on MSD at time of enrollment (Table 2). 
Patients with persistent symptoms despite MSD PPI ther-
apy choosing to undergo traditional surgical therapy11 
may face an additional risk to develop persistent postfun-
doplication symptoms (gas bloat, dysphagia, and inabil-
ity to belch) suggesting that this population is left with 
limited treatment options. In contrast, as confirmed with 
present study, current published literature on TIF sug-
gests that incidence of persistent postfundoplication side 
effects is low after TIF.12
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Figure 4. (A) Patient satisfaction with current health condition as evaluated by GERD-HRQL questionnaire. (B) Individual 
total GERD-HRQL scores in all patients before treatments and at 6-month follow-up. (C) Individual total heartburn scores in 
all patients before treatments and at 6-month follow-up. (D) Individual total RSI scores in all patients before treatments and at 
6-month follow-up.
Abbreviations: GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPIs, proton pump inhibitors; RSI, reflux symptom 
index; TIF, transoral incisionless fundoplication. Red lines represent improvement in the mean scores.
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The study was conducted by general surgeons (4 cen-
ters) and gastroenterologists (3 centers) acting as investi-
gators and device operators. This mix was intentional to 
eliminate a specialty bias. The similarity of outcomes 
achieved by investigators across specialties is encourag-
ing and suggests that the TIF procedure can be performed 
equally well by both foregut surgeons and gastroenterolo-
gists with advanced endoscopic skills.
The Montreal consensus defined regurgitation as the 
perception of flow of refluxed gastric content into the 
mouth or hypopharynx.1 Troublesome symptoms are 
defined as mild symptoms occurring 2 or more days a 
week, or moderate to severe symptoms occurring more 
than 1 day a week.1 Control of troublesome regurgitation 
is viewed in the current literature as the principal short-
coming of PPI therapy.2 Kahrilas et al4 concluded that 
PPIs caused a modest and considerably less symptomatic 
relief of regurgitation compared with heartburn. In our 
study, troublesome regurgitation was eliminated in 97% 
of patients in the TIF arm when compared with 50% in 
the PPI group when MSD were administered. This differ-
ence suggests that rebuilding the mechanical and geo-
metrical characteristics of the gastroesophageal valve is 
important when attempting to control symptoms poten-
tially arising from proximal extend of the refluxate. This 
study confirms the previously reported outcomes with 
regards to elimination of regurgitation15,23,24 and suggests 
that TIF could be an alternative treatment option for this 
subgroup of patients.
Review of the literature yields success rates for LNF 
in eliminating troublesome extraesophageal symptoms 
ranging between 48% and 65%.25-27 In this study, TIF was 
significantly more effective than MSD PPIs (Figure 3) in 
eliminating throat clearing (83% vs 23%), troublesome or 
annoying cough (83% vs 13%), and hoarseness (92% vs 
20%). We believe that patients with extraesophageal 
symptoms achieved positive results because of the fact 
that they had objective evidence of GERD, and had rela-
tively small anatomic defects. TIF could be considered a 
viable alternative for the patient population with a signifi-
cant extraesophageal component provided that the same 
inclusion criteria are used in clinical practice.
Beyond the clinical relevance of the major findings of 
this study related to TIF, we found that MSD of PPIs were 
not better than TIF in eliminating heartburn, healing of 
reflux esophagitis, and normalizing distal EAE. We spec-
ulate that the unexpectedly low rate of healing of esopha-
gitis in the PPI group (38%) may indicate that a higher 
proportion of patients in this study suffered from non-
acid reflux or weakly acid reflux. The published data on 
the normalization of EAE after PPI treatment are lim-
ited.14 Milkes et al28 reported that 50% of patients had 
persistent abnormal EAE despite taking PPIs twice daily. 
Our study reproduces these results in the PPI group. 
Although we performed a medication count and it appears 
that patients complied with their prescribed medical regi-
mens, we recognize that full control of patients’ compli-
ance is difficult to achieve. Therefore, we cannot discount 
the possibility that some patients did not comply with 
prescribed medications influencing the rate of EAE nor-
malization in the control group.
In the TIF group, significant symptoms control (up to 
97%) was not followed by the similar rate of pH normal-
ization (54%). Improvement in patient quality of life and 
healing of esophagitis are often cited as the goals of treat-
ments for GERD, and accordingly are often the endpoints 
of many studies related to GERD therapies.15 The level of 
esophageal acid exposure in patients who were asymp-
tomatic on PPI therapy is poorly addressed in the litera-
ture. Among 4 studies we found, 17% to 80% of patients 
demonstrated abnormal esophageal acid exposure while 
being asymptomatic on PPI therapy.29-32 As this matter 
relates to newer technologies for GERD, Bell et al15 did 
not find association between symptomatic outcomes and 
normalization of esophageal acid exposure after TIF, mir-
roring findings from another study.33 Future studies 
involving pH impedance may better define the relation-
ship between symptomatic outcomes and normalization 
of esophageal acid exposure post TIF and further eluci-
date the effects of TIF and PPIs in patients with nonacid 
reflux.
Patients in the TIF group had a significant improve-
ment in every 48-hour pH parameter, but did not reach 
the levels of pH normalization reported for laparoscopic 
fundoplication.34 It has been argued that the higher rates 
of pH normalization reported post–laparoscopic fundo-
plication result from the creation of a “supercompetent” 
gastroesophageal valve, which may also cause postfun-
doplication side effects such as dysphagia (11%), bloat-
ing (40%), diarrhea (16%), and flatulence (57%) in a 
significant number of patients at 5-year follow-up.11 Such 
occurrences result in patient dissatisfaction, additional 
health care and societal costs and the need for revisional 
procedures or endoscopic esophageal dilatations in cases 
of severe persistent dysphagia. In this study, none of the 
patients in the TIF group reported de novo bloating, dys-
phagia, or flatulence at 6-month follow-up. Although, the 
comparison of postfundoplication symptoms after the 
TIF procedure and after LNF is based on different time 
intervals, we believe that the very limited incidence of 
side effects combined with a solid safety record (no 
reported mortality in more than 13 000 cases performed 
worldwide) represents one of the most attractive aspects 
of TIF procedure.
The only patient with short segment Barrett’s in this 
trial was randomized to the TIF group and was com-
pletely off PPIs with a normalized distal esophageal 
exposure at 6-month follow-up. The role of TIF in the 
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management of Barrett’s metaplasia remains to be defined 
and will no doubt require additional studies. This patient 
will be kept under strict endoscopic surveillance.
Our findings must be interpreted while considering the 
limitations of this study, most notably the short-term fol-
low-up and the potential placebo effect in the TIF group. 
We felt that reporting these encouraging short-term 
results is reasonable given that the recommended treat-
ment for patients with predominant extraesophageal 
symptomatology is aggressive acid reduction using PPIs 
twice daily short-term over a duration of 3 to 4 months.35 
To address the potential placebo effect, another random-
ized trial which includes a sham arm is currently under-
way with early results expected in the near future. One 
may argue that the small sample size (39 in the TIF group 
vs 21 in the PPI group) and unequal randomization allo-
cation could affect our findings. In this context, it is worth 
pointing that the use of unequal randomization ratios will 
only significantly reduce the power of the study if a ratio 
of 3:1 or more is used.36 Furthermore, the study has been 
appropriately powered (80%) to detect significant differ-
ences between the 2 treatment arms. A further potential 
limitation of this study was that the study population was 
heterogeneous with regards to predominant symptom-
atology; we feel that this is reflective of the fact that spe-
cialized GERD practices are increasingly evaluating and 
treating patients with mixed symptomatology. And 
finally, we used randomization and objective pH testing 
to minimize potential bias from an open-label study 
design. To further minimize this bias, all PPI patients 
were offered crossover to TIF after completion of 6-month 
follow-up. We will report these outcomes as results 
become available.
With regard to predictors of success or failures fol-
lowing TIF, a critical analysis of the 4 patients who con-
tinued acid suppressive medication after TIF revealed 
important findings. As previously suggested,15 our study 
also demonstrates that patients with more severe disease 
appear to have a higher likelihood of requiring PPIs after 
TIF. All 4 patients suffered from severe heartburn 
(GERD-HRQL scores >30 on PPIs). Although 10% of 
patients were back on PPI therapy, the significant 
improvement in the QOL scores postprocedure (Figure 
3) suggests that TIF may be a useful therapeutic adjunct 
to PPIs in patients with incomplete symptom control. We 
attempted to define factors predictive of post-treatment 
normalization of esophageal acid exposure. The fact that 
all patients in the study underwent pH testing at screen-
ing and at 6-month follow-up presented a unique oppor-
tunity to define these factors. We observed that 
preprocedure % total time pH < 4 inferior to 10 was 
associated with a high rate of pH normalization after TIF 
(74% [17/23] normalized vs 25% [4/12] normalized if % 
time pH < 4 was ≥10; [P = .004]). Interestingly, the same 
observation could not be made in the PPI group (66% 
normalized [8/12] if % time pH < 4 was inferior to 10 
before vs 33% [3/9] if % time was ≥10 after taking maxi-
mal PPI dose for 6 months [P = .198]). Beyond the previ-
ously defined factors associated with successful 
outcomes such as hiatal hernia ≤2 cm and GERD-HRQL 
<30, this study suggests that preprocedure total % time 
pH < 4 inferior to 10 could be an important factor in 
selecting the most appropriate patients and setting appro-
priate expectations for the TIF procedure in individual 
cases. We plan to report a comprehensive evaluation of 
factors associated with successful outcomes after TIF at 
a longer term follow-up. Also, in this study, we reported 
our results in terms of complete elimination of trouble-
some symptoms and pH normalization over 48 hours 
rather than ≥50% reduction in total scores and % total 
time pH < 4 based on 24 hours. We believe that these 
stricter and more comprehensive evaluation criteria may 
provide a useful reference in assessing patients for less 
invasive GERD therapies.
Based on the results of this study, it would appear that 
the TIF procedure is ideally suited as a treatment alterna-
tive for GERD patients who fall in the so-called “therapy 
gap,” a term often used to describe the 30% to 40% of 
patients who take daily PPIs and who remain unsatisfied 
because of incomplete symptom control.3 These patients 
are often unwilling to undergo a laparoscopic fundoplica-
tion for fear of its side effects. TIF may offer these 
patients the opportunity to safely eliminate their trouble-
some typical and atypical symptoms without the risk of 
developing postfundoplication syndromes.
Conclusion
In conclusion, among select patients presenting with per-
sistent troublesome GERD symptoms and small hiatal 
hernias (≤2 cm), TIF, compared to maximal standard dose 
PPI therapy, resulted in better control of regurgitation and 
a wide range of chronic GERD symptoms while avoiding 
the undesirable postfundoplication syndromes associated 
with laparoscopic antireflux procedure in some patients. 
Patients in the TIF and PPI arms were found to have simi-
lar rates of distal esophageal pH normalization. Despite 
encouraging results from this study, longer term follow-
ups are warranted.
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